Skip to content
Fortaz, Zavicefta(ceftazidime)
Avycaz, Ceptaz, Fortaz, Pentacef, Tazicef, Tazidime, Zavicefta (ceftazidime) is a small molecule pharmaceutical. Ceftazidime was first approved as Fortaz on 1985-07-19. It is used to treat acinetobacter infections, bacterial infections, bacterial meningitis, bacterial pneumonia, and bacterial skin diseases amongst others in the USA. It has been approved in Europe to treat bacterial pneumonia, gram-negative bacterial infections, pneumonia, soft tissue infections, and urinary tract infections.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
musculoskeletal diseasesD009140
respiratory tract diseasesD012140
nervous system diseasesD009422
urogenital diseasesD000091642
hemic and lymphatic diseasesD006425
skin and connective tissue diseasesD017437
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Combinations
Avycaz
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Avibactam sodium
+
Ceftazidime
Tradename
Company
Number
Date
Products
AVYCAZAllerganN-206494 RX2015-02-25
1 products, RLD, RS
Ceftazidime
Tradename
Company
Number
Date
Products
CEFTAZIDIME IN DEXTROSE CONTAINERB. Braun MedicalN-050823 DISCN2011-06-13
2 products, RLD
CEPTAZGSKN-050646 DISCN1990-09-27
4 products
FORTAZPAI PharmaN-050578 DISCN1985-07-19
4 products, RLD
Hide discontinued
Ceftazidime sodium
Tradename
Company
Number
Date
Products
FORTAZ IN PLASTIC CONTAINERPAI PharmaN-050634 DISCN1989-04-28
3 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
avycazNew Drug Application2020-12-24
fortaz New Drug Application2017-07-28
tazicefANDA2023-03-10
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
acinetobacter infectionsEFO_1000792D000151—
bacterial infections—D001424A49
bacterial meningitisEFO_1000831D016920G00
bacterial pneumoniaEFO_1001272D018410J15.9
bacterial skin diseases—D017192—
escherichia coli infectionsEFO_1001318D004927B96.20
feverHP_0001945D005334R50.9
haemophilus infectionsEFO_1001127D006192—
infectious bone diseases—D001850—
klebsiella infectionsEFO_1001353D007710—
Show 9 more
Agency Specific
FDA
EMA
Expiration
Code
AVIBACTAM SODIUM / CEFTAZIDIME, AVYCAZ, ALLERGAN
2025-12-20NPP
2025-02-25GAIN
2020-02-25NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Avibactam Sodium / Ceftazidime, Avycaz, Allergan
89695662032-06-15DP
92843142032-06-15DP
96951222032-06-15DP
84710252031-08-12DP
88354552030-10-08DP
76120872026-11-12DP
71125922026-01-07DS, DPU-282, U-2244, U-2508
ATC Codes
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01D: Other beta-lactam antibacterials in atc
— J01DD: Third-generation cephalosporins
— J01DD02: Ceftazidime
— J01DD52: Ceftazidime and beta-lactamase inhibitor
HCPCS
Code
Description
J0713
Injection, ceftazidime, per 500 mg
J0714
Injection, ceftazidime and avibactam, 0.5 g/0.125 g
Clinical
Clinical Trials
66 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Cystic fibrosisD003550EFO_0000390E841——438
Urinary tract infectionsD014552EFO_0003103N39.0—331—7
Intraabdominal infectionsD059413—22116
InfectionsD007239EFO_0000544——1225
Healthcare-associated pneumoniaD0000772991—1215
Febrile neutropeniaD064147———3—3
Ventilator-associated pneumoniaD053717EFO_1001865J95.851——1113
PeritonitisD010538EFO_0008588K65———123
BacteremiaD016470EFO_0003033R78.81———112
FeverD005334HP_0001945R50.9———1—1
Show 5 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PneumoniaD011014EFO_0003106J18—13—26
Liver cirrhosisD008103EFO_0001422K74.0—11——1
AscitesD001201HP_0001541R18—11——1
Esophageal achalasiaD004931HP_0002571K22.0—11——1
Staphylococcal skin infectionsD013207EFO_1001849L00——1——1
Infectious skin diseasesD012874——1——1
Bacterial skin diseasesD017192——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Bacterial infectionsD001424A4911——23
MelioidosisD008554A24.9—1——12
Gram-negative bacterial infectionsD016905—1———1
MeningitisD008581EFO_0000584G03—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—2————2
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SepsisD018805A41.9————22
Chronic bronchitisD029481J42————11
Bacterial meningitisD016920EFO_1000831G00————11
AppendicitisD001064EFO_0007149K37————11
Critical illnessD016638————11
Renal insufficiencyD051437HP_0000083N19————11
Chronic kidney failureD007676EFO_0003884N18.6————11
Communicable diseasesD003141————11
Respiratory distress syndromeD012128EFO_1000637J80————11
Cross infectionD003428————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCEFTAZIDIME
INNceftazidime
Description
Ceftazidime is a third-generation cephalosporin antibiotic bearing pyridinium-1-ylmethyl and {[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetamido groups at positions 3 and 7, respectively, of the cephem skeleton. It has a role as an antibacterial drug, an EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor and a drug allergen. It is a cephalosporin and an oxime O-ether. It is a conjugate acid of a ceftazidime(1-).
Classification
Small molecule
Drug classcephalosporins
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC(C)(O/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(C[n+]3ccccc3)CS[C@H]12)c1csc(N)n1)C(=O)O
Identifiers
PDB—
CAS-ID72558-82-8
RxCUI2191
ChEMBL IDCHEMBL44354
ChEBI ID3508
PubChem CID5481173
DrugBankDB00438
UNII IDDZR1ENT301 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Avycaz - Allergan
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Avycaz - Warner Chilcott
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Zavicefta - Pfizer
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 31,566 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
3,477 adverse events reported
View more details